Jaclyn M Beca

5PUBLICATIONS
12CO-AUTHORS
Predictive and prognostic markersEconomic models and forecastingMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 30, 2025
Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada.

Jaclyn M Beca, Stephanie Gosselin, Don Husereau

|Jun 25, 2025
Impact of Limited Sample Size and Follow-up on Partitioned Survival and Multistate Modeling-Based Health Economic Models: A Simulation Study.

Jaclyn M Beca, Kelvin K W Chan, David M J Naimark

|May 15, 2023
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.

Ambica Parmar, Wei Fang Dai, Francois Dionne

|Jul 02, 2021
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces.

Reka E Pataky, Jaclyn Beca, David Tran

|Aug 15, 2020
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.

Steven Habbous, Helen Guo, Jaclyn Beca

Pageof 1

Frequent Collaborators

3 joint publications

Kelvin K W Chan

1 joint publications

Steven Habbous

1 joint publications

Wei Fang Dai

1 joint publications

Wanrudee Isaranuwatchai